President Donald Trump's sweeping new trade tariffs sent shockwaves through global markets on Thursday, triggering a massive sell-off that echoed the COVID-19 pandemic-era routs, as investor risk appetite vanished in a flash.
Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.
The iShares Russell 2000 ETF which tracks small-cap stocks, plunged 5% on Thursday. President Donald Trump's sweeping reciprocal tariffs roiled financial markets and heightened concerns about an economic downturn.
Asian markets closed mostly lower on Thursday, led by Japan’s Nikkei 225 Index, which plunged 2.77% before settling at an eight-month low, while European stocks started sharply lower.
The research firm surmised that the design contract Vishay Precision Group secured in late 2023 with an unnamed, leading humanoid robot developer is none other than Tesla's Optimus.
Though the FDA was set to give full approval to the vaccine, senior leaders at the agency have now said that the company’s application needs more data and is unlikely to be approved soon, The Wall Street Journal reported.
Wall Street extends gains on Wednesday, as investors remain resilient in their risk appetite despite the looming announcement of sweeping trade tariffs by President Donald Trump.
The medical technology company now expects net sales to be $285 to $288 million for the fiscal year 2025, up from previously issued guidance of $282 to $288 million, owing to increased medical technology net sales.
Following the worst quarterly performance for U.S. stocks in over two years, caution dominated Wall Street as investors awaited details on the tariff plans expected from the Trump administration on Wednesday.
ouis Navellier expects the earnings season to give investors new confidence regarding the near-term gains of AI spending, potentially lifting sentiment toward tech stocks.
Annualized recurring revenue, a key operating metric, jumped 48% YoY to $836 million, with the growth rate accelerating from the 46% pace in the previous quarter.
Risk sentiment remains under pressure at the start of the week on Wall Street, with tech-heavy indexes sliding while commodities advance, as traders fear a new wave of price pressures following the upcoming tariffs announcement.
The Finchat-compiled consensus estimates call for adjusted earnings per share (EPS) of $1.06 and revenue of $235.64 million for the first quarter of the fiscal year 2025.
With last week's move to the downside we now have to consider new swing lows for indices, with the ones established a couple of weeks ago unlikely to hold.
The positives are elusive. The breadth indicators show the possibility of a serious decline in prices in the near future. But at least the bottom for this decline should be easy to identify by a sharp decrease in the number of new lows.
